Gilead acquired Immunomedics in 2020 for US $21 Bn. The main drug the latter had was Trodelvy which was approved by FDA for use in cancer treatment.
The interesting bit for me from a Bloomberg article today was that the Gilead CEO called Trodelvy as “pipeline in a product” which could have a wide variety of uses. I think this is a good way of marketing Zantrene to BP
(this is a cooler title than just as a multi-use drug- we are selling you a pipeline!)
Gilead acquired Immunomedics in 2020 for US $21 Bn. The main...
-
- There are more pages in this discussion • 1,746 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
-0.005(0.28%) |
Mkt cap ! $303.3M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.84 | $1.78 | $133.8K | 73.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15072 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 1793 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |